Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
One of our regular commentators — Dr. John McHugh — has apparently developed an “app” that can be used by newly diagnosed men on their “smart phones” to help them evaluate their options after an initial diagnosis of prostate cancer.
Filed under: Diagnosis, Management, Risk | 1 Comment »
Many readers may be interested in an article on active surveillance and other forms of expectant management by Khurana and Stephenson that appears on the front page of the November issue of the AUA News. This article is based on a poster presented by Khurana et al. at the annual meeting of the American Urological [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: active surveillance, expectant management, observation, watchful waiting | 1 Comment »
There are few published data on the efficacy and safety of PDE-5 inhibitors (e.g., sildenafil/Viagra and tadalafil/Cialis) in management of erectile function after the first-line treatment of prostate cancer with radiation therapy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: erectile dysfunction, radiation therapy, tadalafil | Leave a Comment »
Newly reported research from a team at the Centenary Institute in Sydney, Australia, has suggested a very different way in which it may be possible to significantly delay or manage the progression of prostate cancer.
Filed under: Drugs in development, Management, Prevention | Tagged: blockade, leucine, Management, Prevention | 2 Comments »
A new article by a group of German researchers offers information from a systematic review of randomized, controlled trials of different types of physical activity in the management of prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | 3 Comments »
According to a Reuters report and a media release this morning, Medivation has announced that interim results of the Phase III AFFIRM trial showed a 4.8-month survival benefit for treatment with MDV3100 compared to a placebo in men with metastatic, castration-resistant prostate cancer after treatment with docetaxel-based chemotherapy.
Filed under: Drugs in development, Management, Treatment | Tagged: AFFIRM, mCRPC, MDV3100, outcome | 2 Comments »
In light of the publication this week of data by Warde et al. on external beam radiation therapy + lifelong total androgen deprivation (ADT) as a first-line treatment for high-risk, localized and locally advanced prostate cancer (click here for commentary), it is interesting to note an article from another research group outlining experience with a [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: "high risk", localized, locally advanced, prostatectomy, robot-assisted | Leave a Comment »
The big news today is the publication, in The Lancet, of the interim results of the NCIC CTG PR.3/MRC UK PR07 trial, originally presented by Warde et al. at the annual meeting of the American Society for Clinical Oncology in June 2010 and then by Mason et al. at the annual meeting of the American [...]
Filed under: Diagnosis, Management, Treatment, Risk | Tagged: localized, ADT, "high risk", androgen deprivation therapy, EBRT, external beam radiation therapy, locally advanced | Leave a Comment »
An article by a highly regarded specialist in medical oncology in the most recent issue of The ASCO Post discusses recent recommendations from the U.S. Preventive Services Task Force (USPSTF).
Filed under: Diagnosis, Risk | Tagged: Diagnosis, opinion, recommendation, risk, USPSTF | 11 Comments »
According to a new report from a team of Portuguese and Egyptian researchers, an unnamed, wrapped, Ptolemaic mummy from about 285–230 BCE has been shown to have died with (and probably of) metastatic prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer | 1 Comment »
Accoring to a Bloomberg Businessweek report and information on the Exelixis corporate web site, the company is planning two multi-center, randomized, Phase III clinical trials of the investigational agent cabozantinib (a.k.a., XL184) in metastatic, castration-resistant prostate cancer (mCRPC):
Filed under: Drugs in development, Management, Treatment | Tagged: cabozantinib, mCRPC, pain, Phase III, trial | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
Lack of transparency re public “input” to USPSTF is rather sad
According to a new article by Andy Pollack on the New York Times Health blog just before 1:00 p.m. EST today, the U.S. Preventive Services Task Force (USPSTF) has managed to add to public confusion about its process for what was originally described as public “comment” on current draft recommendations (regarding screening tests for prostate [...]
Filed under: Diagnosis, Risk | Tagged: public comment, recommendation, transparency, USPSTF | 8 Comments »